301 related articles for article (PubMed ID: 8336189)
1. OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures.
Xu FJ; Yu YH; Daly L; DeSombre K; Anselmino L; Hass GM; Berchuck A; Soper JT; Clarke-Pearson DL; Boyer C
J Clin Oncol; 1993 Aug; 11(8):1506-10. PubMed ID: 8336189
[TBL] [Abstract][Full Text] [Related]
2. OVX1 as a marker for early stage endometrial carcinoma.
Xu FJ; Yu YH; Daly L; Anselmino L; Hass GM; Berchuck A; Rodriguez GC; Soper JT; Clarke-Pearson DL; Hollis D
Cancer; 1994 Apr; 73(7):1855-8. PubMed ID: 8137210
[TBL] [Abstract][Full Text] [Related]
3. Is OVX1 a suitable marker for endometrial cancer?
Beck EP; Wagner M; Anselmino L; Xu F; Bast RC; Jaeger W
Gynecol Oncol; 1997 May; 65(2):291-6. PubMed ID: 9159340
[TBL] [Abstract][Full Text] [Related]
4. Clinical evaluation of circulating serum sialyl Tn antigen levels in patients with epithelial ovarian cancer.
Kobayashi H; Terao T; Kawashima Y
J Clin Oncol; 1991 Jun; 9(6):983-7. PubMed ID: 1851822
[TBL] [Abstract][Full Text] [Related]
5. Elevation of multiple serum markers in patients with stage I ovarian cancer.
Woolas RP; Xu FJ; Jacobs IJ; Yu YH; Daly L; Berchuck A; Soper JT; Clarke-Pearson DL; Oram DH; Bast RC
J Natl Cancer Inst; 1993 Nov; 85(21):1748-51. PubMed ID: 8411259
[TBL] [Abstract][Full Text] [Related]
6. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal.
van Haaften-Day C; Shen Y; Xu F; Yu Y; Berchuck A; Havrilesky LJ; de Bruijn HW; van der Zee AG; Bast RC; Hacker NF
Cancer; 2001 Dec; 92(11):2837-44. PubMed ID: 11753957
[TBL] [Abstract][Full Text] [Related]
7. Serum sialyl Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer.
Kobayashi H; Terao T; Kawashima Y
J Clin Oncol; 1992 Jan; 10(1):95-101. PubMed ID: 1727929
[TBL] [Abstract][Full Text] [Related]
8. Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass.
Hogdall EV; Høgdall CK; Tingulstad S; Hagen B; Nustad K; Xu FJ; Bast RC; Jacobs IJ
Int J Cancer; 2000 Nov; 89(6):519-23. PubMed ID: 11102897
[TBL] [Abstract][Full Text] [Related]
9. CA 125 serum levels correlated with second-look operations among ovarian cancer patients.
Berek JS; Knapp RC; Malkasian GD; Lavin PT; Whitney C; Niloff JM; Bast RC
Obstet Gynecol; 1986 May; 67(5):685-9. PubMed ID: 3457330
[TBL] [Abstract][Full Text] [Related]
10. Use of CA 125 to monitor patients with ovarian epithelial carcinomas.
Podczaski E; Whitney C; Manetta A; Larson JE; Kirk J; Stevens CW; Lyter J; Mortel R
Gynecol Oncol; 1989 May; 33(2):193-7. PubMed ID: 2703180
[TBL] [Abstract][Full Text] [Related]
11. [Relationship between serum CA125 level and second-look findings in ovarian cancers].
Liu LY
Zhonghua Zhong Liu Za Zhi; 1992 Jul; 14(4):287-9. PubMed ID: 1327702
[TBL] [Abstract][Full Text] [Related]
12. OVX1 and CEA in patients with colon carcinoma, colon polyps and benign colon disorders.
Martell RE; Xu FJ; Davis WZ; Anselmino L; Yu YH; Daly L; Bast RC
Int J Biol Markers; 1998; 13(3):145-9. PubMed ID: 10079388
[TBL] [Abstract][Full Text] [Related]
13. Serum levels of CA 125 and histological findings at second-look laparotomy in ovarian carcinoma.
Meier W; Stieber P; Eiermann W; Schneider A; Fateh-Moghadam A; Hepp H
Gynecol Oncol; 1989 Oct; 35(1):44-6. PubMed ID: 2792900
[TBL] [Abstract][Full Text] [Related]
14. The prognostic implications of low serum CA 125 levels prior to the second-look operation for stage III and IV epithelial ovarian cancer.
Gallion HH; Hunter JE; van Nagell JR; Averette HE; Cain JM; Copeland LJ; Higgins RV; Husseinzadeh N; Nahhas WA; Partridge EE
Gynecol Oncol; 1992 Jul; 46(1):29-32. PubMed ID: 1634137
[TBL] [Abstract][Full Text] [Related]
15. [CA 125 (cancer antigen 125), a new tumor associated antigen recognized by monoclonal antibody].
Suzuki H; Teshima K; Noda K
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2719-23. PubMed ID: 6594978
[TBL] [Abstract][Full Text] [Related]
16. Does serum CA-125 level prior to second-look laparotomy for invasive ovarian adenocarcinoma predict size of residual disease?
Patsner B; Orr JW; Mann WJ; Taylor PT; Partridge E; Allmen T
Gynecol Oncol; 1990 Sep; 38(3):373-6. PubMed ID: 2227551
[TBL] [Abstract][Full Text] [Related]
17. [Serum CA 125 values and histologic findings at the time of second-look laparotomy in ovarian cancer].
Meier W; Stieber P; Fateh-Moghadam A; Eiermann W; Hepp H
Geburtshilfe Frauenheilkd; 1988 May; 48(5):331-3. PubMed ID: 3165078
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of second-look laparotomy for ovarian cancer: second-look vs. serum CA125.
Liu L; Hong W; Hou Y; Yao Z; Wu A; Wang X
Chin Med Sci J; 1991 Jun; 6(2):96-9. PubMed ID: 1804384
[TBL] [Abstract][Full Text] [Related]
19. Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer.
Rubin SC; Hoskins WJ; Hakes TB; Markman M; Reichman BS; Chapman D; Lewis JL
Am J Obstet Gynecol; 1989 Mar; 160(3):667-71. PubMed ID: 2648838
[TBL] [Abstract][Full Text] [Related]
20. Carcinoma-associated mucin serum markers CA M26 and CA M29: efficacy in detecting and monitoring patients with cancer of the breast, colon, ovary, endometrium and cervix.
Yedema KA; Kenemans P; Wobbes T; van Kamp GJ; de Bruijn HW; Thomas CM; Massuger LF; Schijf CP; Bon GG; Vermorken JB
Int J Cancer; 1991 Jan; 47(2):170-9. PubMed ID: 1988362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]